Search
forLearn
5 / 801 resultslearn ascorbic acid
learn Selenium AAC
learn avocado
learn AHAs
Research
5 / 108 results
research Development of gene therapy for inner ear disease: Using bilateral vestibular hypofunction as a vehicle for translational research
Gene therapy, especially using atoh1, shows promise for creating functional sensory hair cells in the inner ear, but dosing and side effects need to be managed for clinical application.
research Basic concepts, current evidence, and future potential for gene therapy in managing cutaneous wounds
Gene therapy shows promise for improving wound healing, but more research is needed for human use.
research Pre-clinical non-viral vectors exploited forin vivoCRISPR/Cas9 gene editing: an overview
Non-viral vectors show promise for safe and effective CRISPR/Cas9 gene editing in treating diseases.
research Treatment of Cystathionine β-Synthase Deficiency in Mice Using a Minicircle-Based Naked DNA Vector
MC-DNA vector-based gene therapy can temporarily treat CBS deficiency in mice.
research Gene therapy for alopecia in type II rickets model rats using vitamin D receptor-expressing adenovirus vector
Gene therapy helped rats with a specific type of rickets grow hair without severe inflammation.
Community Join
5 / 1000+ resultscommunity Has anyone done research on Absci's AI‑driven antibody platform? Seeking your thoughts!
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
community Topical VPA - Anyone experiences here?
The conversation is about using topical valproic acid (VPA) for hair loss, focusing on its application method, usage frequency, and combination with other treatments like micro-needling. No specific experiences with VPA were shared.
community Targeting multiple AGA mechanisms with commonly available substances
community NW5 advice current treatments AGA
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.